METHODS:
We performed a retrospective analysis of 492 subjects who underwent gastric bypass bariatric surgery at a single center in Switzerland from January 1997 through December 2004; routine perioperative liver biopsies were collected, analyzed histologically, and RNA was isolated. We collected data on overall survival and clinical and biochemical parameters and compared these with data from propensity score-matched subjects participating in the third National Health and Nutrition Examination Survey (NHANES III). We used liver biopsies to identify bariatric surgery patients with NASH; NHANES III participants with NASH were identified based on a hyperechogenic liver at ultrasound and increased alanine transaminase levels. We analyzed a 32-gene signature associated with NAFLD severity in the liver tissues collected from 47 bariatric surgery patients with NASH, and assessed its prognostic features using nearest template prediction and survival analysis.
RESULTS:
At baseline, the median body mass index of patients who underwent bariatric surgery was 43.6 kg/m 2 ; based on histologic findings, 12% had NASH and 16% had fibrosis. During a median follow-up of 10.2 years after the surgery, 4.2% of the subjects died. In multivariable Cox regression, the presence of NASH (hazard ratio [HR], 2.9; P [ .02) and arterial hypertension (HR, 3.9; P [ .02) were associated with overall mortality. When bariatric surgery patients were matched with NHANES III participants, bariatric surgery reduced the risk of death during the follow-up period (HR, 0.54; P [ .04). However, bariatric surgery patients with NASH did not have a reduced risk of death compared with NHANES III participants with NASH (HR, 0.90; P [ .85). We identified an expression pattern of 32 genes in liver tissues from patients with NASH that was associated with increased risk of death in multivariable analysis (HR, 7.7; P [ .045).
CONCLUSIONS:
Histologically proven NASH is associated with increased risk of death within a median follow-up of 10.2 years after bariatric surgery, compared with patients who undergo bariatric surgery without NASH. The survival benefit of bariatric surgery in subjects with NASH may be reduced. A 32-gene expression pattern identified patients with NASH who underwent bariatric surgery and had shorter survival times.
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, defined as a body mass index (BMI) >30 kg/m 2 , is a major public health issue affecting 34.9% of adults in the United States and costing the U.S. economy an estimated $148 billion in 2008, or almost 10% of total U.S. healthcare spending. 1, 2 Globally, the prevalence of overweight (BMI >25 kg/m 2 ) increased from 857 million to 2.1 billion (29%-37% of the world population) between 1980 and 2013. 3 Obesity is strongly associated with nonalcoholic fatty liver disease (NAFLD), a clinicopathologic spectrum ranging from hepatic steatosis to nonalcoholic steatohepatitis (NASH) and cirrhosis. NAFLD is emerging as the most common liver disease in the Western world, with up to one-third of adults affected in the United States. 4, 5 The prevalence of NAFLD in the setting of morbid obesity and bariatric surgery ranges from 63% to 99% for steatosis >5%, 10% to 58% for NASH, and 7% to 74% for fibrosis depending on definition, diagnostic criteria, and the distribution of risk factors in the specific population studied. 6 Bariatric surgery is now widely performed for severely obese subjects, and has been associated with weight reduction and an improvement in obesity-related conditions including type 2 diabetes, arterial hypertension, and dyslipidemia. 7 Despite increasing data from case-control or cohort studies suggesting that bariatric surgery is associated with improved long-term survival, the mortality benefit depends on the risk-profile of the population with 1 study in Veterans Affairs medical centers reporting no benefit. [8] [9] [10] Most prognostic studies in patients treated with bariatric surgery have focused on short-term postoperative outcomes. 11, 12 Baseline factors associated with long-term mortality post bariatric surgery have not been fully established, although age, male sex, BMI >50 kg/m 2 , presence of comorbid conditions (including diabetes, cardiovascular disease), and active smoking have been proposed. 9, 13, 14 In particular, despite the high prevalence of NAFLD/NASH in this population, its relevance in long-term outcome after bariatric surgery is unknown.
We aimed to study the prognostic relevance of histologic and molecular parameters derived from liver biopsy specimens, on overall long-term survival in a well-characterized single-center cohort of obese patients undergoing bariatric surgery.
Materials and Methods
Patient Cohort (Geneva Bariatric Surgery Cohort)
Five hundred severely obese patients consecutively underwent bariatric surgery (Roux-en-Y gastric bypass surgery) at Geneva University Hospital, a tertiary hospital serving the area around Geneva, Switzerland, between June 1997 and December 2004 (Geneva bariatric surgery cohort). 15 During surgery, patients underwent systematic cholecystectomy and left-lobe (segment 3) wedgeresection or needle liver biopsy. Patients were excluded from the study if they had chronic hepatitis B virus or hepatitis C virus infection at baseline, no available baseline liver biopsy tissue, or previous weight-losing surgery ( Figure 1 ). Patients with significant substance abuse, including alcohol abuse (defined as >14 units of alcohol per week), were excluded from surgery (see Supplementary Methods for additional details). This study was approved by the Institutional Review Board of Geneva University Hospital (protocol number , and the requirement for informed consent from the patients was waived because of the retrospective nature of this study.
Outcome Assessment
The main outcome of interest was overall survival. Mortality data were obtained prospectively or, if the patient was lost to follow-up, assessed from the cantonal registry of Geneva. Cause of death was extracted from electronic medical records at our institution. Percentage excess BMI loss was defined as ([preoperative BMI À postoperative BMI] Â 100) / (preoperative BMI À 25). All endpoints, assessed variables, and analyses were preplanned (see Supplementary Methods for additional details).
Histologic Assessment of Liver Biopsy
All histologic liver biopsy specimens were reviewed by an experienced liver histopathologist (L.R.-B.) blinded 
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Comparison With the National Health and Nutrition Examination Survey III Cohort
To assess whether overall survival in the Geneva cohort differed from a control obese population, we performed propensity-score matching of the Geneva cohort subjects with subjects from the third US National Health and Nutrition Examination Survey (NHANES III) 18 and compared survival of the subjects. A subset of the NHANES III cohort, who likely had NASH based on elevated alanine transaminase (ALT; >30 IU/L in men and >19 IU/L in women) and at least moderate hepatic steatosis by ultrasound (834 subjects: NHANES III NASH cohort), was propensity-score matched to the NASH subjects in the Geneva bariatric surgery cohort (see Supplementary Methods for additional details).
Tissue Processing, RNA Extraction, and Gene Expression Profiling All NASH subjects with sufficient remaining formalinfixed, paraffin-embedded hepatic tissue for RNA extraction (n ¼ 47) were included for gene expression profiling. Briefly, total RNA was extracted from 5 formalin-fixed, paraffin-embedded tissue sections 5-mm thick using the High Pure RNA paraffin kit (Roche
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Statistical and Bioinformatics Analysis
Continuous and categorical variables were tested using Wilcoxon rank sum test and Fisher exact test, respectively. Association of the baseline variables with clinical outcomes were evaluated using univariable and multivariable Cox regression modelling. Propensity score matching was performed nonparametrically using nearest-neighbor 1 to 1 matching, based on the following variables: BMI, sex, age, presence of diabetes, arterial hypertension, level of bilirubin, aspartate aminotransferase, g-glutamyltransferase, and total cholesterol (see Supplementary Methods for additional details).
A prognostic 32-gene signature reported in our previous study 19 was used to perform prognostic prediction by using nearest template prediction algorithm 20 implemented in GenePattern. Gene regulatory network was identified by using Multiscale Embedded Gene Co-expression Network Analysis. 21, 22 All statistical and bioinformatics analyses were performed using GenePattern and the R statistical package version 3.1 (www.rproject.org).
Results
Patient Characteristics of the Geneva Cohort
Eight of the 500 consecutively enrolled subjects were excluded because of absence of liver biopsy or prior bariatric surgery (Figure 1 ). Median baseline weight and BMI of the 492 patients included were 118 kg and 43.6 kg/m 2 , respectively. Table 1 summarizes other baseline characteristics. At baseline histology (84% wedgeresection biopsy), 89% had steatosis in more than 5% of hepatocytes, 12% had NASH, and 4% had fibrosis stage 2 or greater (Table 2) . Compared with patients without NASH, patients with NASH were more likely to be male, have diabetes, have hypertension, be previous or current smokers, and to be older, whereas subjects with fibrosis were more likely to be male and have diabetes (Table 1) .
Prospectively assessed weight and BMI was available in 81%, 67%, 53%, and 34% at 1, 2, 3, and 5 years after bariatric surgery, respectively (Supplementary Table 1 ). Median weight loss and excess BMI loss at 1 year after bariatric surgery were 38 kg and 74%, respectively, similar to other reports and systematic reviews of bariatric surgery effectiveness. 7 No patient required bariatric surgery reversal. In univariable and multivariable analysis, excess BMI loss >50% was not associated with features at liver histology but inversely correlated to male sex and baseline BMI >45 kg/m 2 (Supplementary Table 2 ).
Overall Survival
Median follow-up of the Geneva cohort was 10.2 years (7.0-12 years). Overall, 21 of 492 (4.3%) individuals died during follow-up; causes of death were cerebrovascular disease in 2 of 21, nonhepatic neoplasia in 4 of 21 (all more than 5 years after bariatric surgery), sepsis in 7 of 21 (not at time of initial surgery), other causes in 7 of 21 patients (including pulmonary embolus, suicide, accident, and 1 cirrhosis initially attributed to alcohol liver disease but reassessed as multifactorial etiology because of the short history of alcohol consumption before death), and 3 of 21 unknown. When stratified by cause of death, NASH was associated with death from sepsis in univariable analysis along with other baseline factors (Supplementary Table 3 ), whereas fibrosis had borderline significance (P ¼ .067). Events were too rare in the other causes of death to test association with baseline factors.
Baseline factors associated with overall mortality in univariable survival were male sex, age >50 years, presence of diabetes, arterial hypertension, presence of histologic NASH and liver fibrosis (Table 3 and Figure 2A and B). In Cox regression multivariable stepwise Akaike information criteria model selection only NASH (hazard ratio [HR], 2.9; P ¼ .02) and arterial hypertension (HR, 3.9; P ¼ .02) were independently associated with overall mortality (Table 3) . Neither liver fibrosis nor the interaction term between NASH and liver fibrosis were associated with overall mortality in the multivariable Cox regression.
To further clarify whether metabolic cofactors were driving the association between increased mortality and NASH, we performed a matched case-control analysis within the Geneva cohort. We matched the 59 NASH subjects with 59 non-NASH control subjects for age, presence of diabetes, and arterial hypertension. This yielded 59 pairs of NASH cases and matched non-NASH control subjects with identical proportions of diabetes (46%), arterial hypertension (51%), and age >50 years (34%), although as expected aspartate aminotransferase, ALT, and g-glutamyltransferase were significantly elevated in the NASH group (Supplementary Table 4 NASH at baseline biopsy was still associated with increased long-term mortality (HR, 8.8; 95% confidence interval, 1.1-70; P ¼ .04).
When comparing baseline liver histology between subjects alive and dead at end of follow-up, deceased subjects had a higher proportion of NASH (38% vs 11%; P ¼ .01), fibrosis (38% vs 18%; P ¼ .045), a higher median NAS score (3 vs 2; P < .001), and more advanced fibrosis (P ¼ .03) (Supplementary Table 5 ). In survival analysis, individuals with a NAS score !5 had significantly higher mortality than patients with a NAS score of 2 (P < .001), whereas patients with fibrosis stage 1 and stage !2 had a significantly increased mortality than patients without fibrosis (P ¼ .048 and P ¼ .005, respectively) ( Figure 2C and D and Supplementary Table 6 ).
Comparison With Matched Obese Subjects in NHANES III
To assess the effect of bariatric surgery on the survival of obese patients, the Geneva cohort was matched, using propensity-score matching, to 18,723 subjects from the NHANES III cohort (Figure 1 : propensity-score matching #1). This yielded 335 matched pairs of patients with similar baseline characteristics (Supplementary Table 7 , Supplementary Figure 1A and B). Mortality was significantly reduced in the patients undergoing bariatric surgery in univariable and multivariable analysis (HR, 0.54; P ¼ .035) ( Figure 2E, Supplementary Table 8 ).
To assess the potential impact of bariatric surgery on overall survival in patients with NASH, we matched the subset of patients in the Geneva cohort with histologic NASH (n ¼ 59) with subjects from NHANES III with at least moderate steatosis on liver ultrasound and raised ALT (Figure 1 : propensity-score matching #2). In the Geneva cohort, when compared with the histologic gold standard, this surrogate marker of NASH had a sensitivity of 74%, specificity of 96%, positive predictive value of 83%, and negative predictive value of 93% for the diagnosis of NASH. This index was confirmed to be prognostic in the Geneva cohort because the 145 subjects with steatosis and raised ALT had increased mortality (HR, 3.7; P ¼ .003). This matching yielded 41 pairs of subjects with similar baseline characteristics despite higher ferritin in the NHANES III cohort (Supplementary Table 9 , Supplementary Figure 2A and B) . In this analysis, bariatric surgery was not significantly associated with reduced survival (Figure 2F ), whereas older age was associated with worse survival (Supplementary Table 10 ).
Gene Signature-Based Prognostication in Patients With NASH
We next assessed whether molecular-based risk assessment in hepatic tissue of subjects undergoing bariatric surgery could improve risk stratification, especially in patients with NASH. Forty-seven NASH subjects had available formalin-fixed, paraffin-embedded tissue blocks for transcriptome analysis. Median BMI and weight were 44.6 kg/m 2 and 125 kg, respectively; median NAS was 5; and 7 subjects (15%) died during follow-up (Supplementary Table 11 ). A previously published 32-gene signature 19 (Supplementary Table 12 ) was found to be significantly associated with NAFLD severity in a previous cohort of 72 NAFLD subjects 23 (Supplementary Figure 3) . The 32-gene poor prognosis prediction was associated with increased overall mortality in Geneva cohort NASH subjects (log-rank P ¼ .03). In multivariable Cox regression modelling, age >50 years (HR, 14; P ¼ .02) and 32-gene signature poor prognosis prediction (HR, 9.0; P ¼ .045) were independently associated with increased overall mortality ( Figure 3A and B, Supplementary Table 13 ).
In the NASH gene expression profiles, Multiscale Embedded Gene Co-expression Network Analysis identified 9 distinct gene regulatory modules ( Figure 3C , Supplementary Table 14) . A tightly clustered gene module (number 4) was centered on a hub gene, epidermal growth factor, a fibrogenic and carcinogenic driver implicated as an hepatocellular carcinoma chemoprevention target in our previous study, 24 which has led to initiation of a clinical trial of epidermal growth factor receptor inhibitor, erlotinib (clinicaltrials.gov, NCT02273362). Module number 6 was enriched with tumor necrosis factor-a signaling via nuclear factor-kB pathway (P < .001), indicating presence of inflammatory pathway activation in NASH-affected liver (Supplementary Table 15 ). Module number 5 was enriched with collagen-encoding genes, TGF-a target genes, such as TGFB1I1, epithelial-mesenchymal transition pathway (P ¼ .002), and 2 previously published hepatic stellate cell signatures, 25, 26 evidencing activated fibrogenesis (P < .05).
Discussion
In this retrospective, single-center cohort, we have demonstrated that presence of NASH at baseline liver histology of severely obese subjects undergoing bariatric surgery is associated with increased long-term mortality compared with those without NASH. Of greater concern, despite reduced overall mortality for obese subjects undergoing bariatric surgery compared with matched, nonsurgical, subjects, patients with NASH at baseline did not have improved survival after bariatric surgery. Importantly, we identified that a poor prognosis 32-gene signature prediction 19 was associated with NAFLD severity in a previously published cohort of 72 subjects with NAFLD 23 and could identify poor prognosis NASH subjects in the Geneva cohort with increased long-term mortality compared with control obese NASH subjects.
To our knowledge, our study is the first analysis of the relationship between perioperative findings at liver biopsy and long-term outcomes after bariatric surgery.
Previous reports have demonstrated that the beneficial effects of bariatric surgery are not only linked to a reduction of body weight but also to an improvement in metabolic parameters, such as type 2 diabetes, hypertension, and dyslipidemia. 7 Paired liver biopsy studies have also demonstrated a reduction of NASH prevalence over 5 years after surgery and improvement of fibrosis. 27, 28 Nevertheless, despite these encouraging results, our data suggest that subjects with baseline NASH have an increased mortality after bariatric surgery and their overall survival may not improve after bariatric surgery despite no significant difference in weight loss. Further studies will have to examine whether persistence of diabetes was associated with NASH and longterm mortality. Interestingly, when performing a subgroup analysis on cause of death in our cohort, NASH was associated with mortality from sepsis. This could suggest that the association between NASH and mortality in our study captures a risk factor for nonhepatic mortality as underlined by the finding that only 1 person died from liver-related cause in our cohort. This could also explain why the association with overall mortality and NASH seemed stronger than the association with fibrosis, as opposed to longitudinal studies in nonbariatric surgery NAFLD subjects, indicating again that NASH could be a better predictor of overall, nonhepatic mortality, whereas fibrosis may better predict liverrelated mortality. 29, 30 In addition, the finding that tumor necrosis factor-a signaling was enriched in 1 of the gene regulatory modules may suggest a link with altered intestinal permeability 31 and possibly a lack of reversal to a more favorable metabolic profile in a subgroup of individuals captured by the gene signature.
Potential limitations of our study include the selection of different populations for our bariatric surgery cohort and the U.S.-based control NHANES III cohort, although we performed careful propensity-score matching to minimize bias with well-matched major predictors of prognosis, such as age, or features of the metabolic syndrome. Although the diagnosis of NASH could not be histologically documented in the control NHANES III cohort because of the absence of liver biopsy, we believe that our 2-tier selection of patients, first by selecting subjects with steatosis and raised ALT then by propensity-matching these subjects to the histologically documented Geneva cohort NASH subjects, limited potential biases. In addition, we tested the diagnostic performance of this previously reported 32, 33 noninvasive definition of NASH in the Geneva cohort and confirmed that it was associated with prognosis. Finally, although potential bariatric surgery in the NHANES III control group could represent a bias, only 2.9% of adults eligible for bariatric surgery in the United States underwent the procedure between 1998 and 2006, suggesting that the impact of potential bariatric surgery in the control NHANES III group would be relatively low. 34 In conclusion, we have shown that features found at baseline liver histology predict long-term overall survival in severely obese subjects undergoing bariatric surgery. Our results also suggest that a subgroup of subjects with NASH and a poor prognosis 32-gene signature is at particularly high risk of long-term mortality after bariatric surgery and may require specific management and follow-up. We believe these findings also reinforce the role of systematic perioperative liver biopsy in subjects undergoing bariatric surgery as a prognostic and diagnostic tool. Further experimental and clinical studies are required to characterize and define these novel findings . 929  930  931  932  933  934  935  936  937  938  939  940  941  942  943  944  945  946  947  948  949  950  951  952  953  954  955  956  957  958  959  960  961  962  963  964  965  966  967  968  969  970  971  972  973  974  975  976  977  978  979  980  981  982  983  984  985 986 Microarray data are available at the National Center for Biotechnology Information Gene Expression Omnibus (GSE69248). Reviewer access link to the transcriptome profiling dataset can be found at http://www.ncbi.nlm.nih.gov/ geo/query/acc.cgi?token¼clsncgimvbajneb&acc¼GSE69248
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